VEA
CTMX icon

Virtus ETF Advisers’s CytomX Therapeutics CTMX Stock Holding History

Virtus ETF Advisers’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-25,634
Closed -$68K – 450
2022
Q1 		$68K Sell
25,634
-1,516
-6% -$5.82K 0.03% 354
2021
Q4 		$118K Sell
27,150
-2,208
-8% -$12.9K 0.04% 371
2021
Q3 		$149K Sell
29,358
-1,538
-5% -$8.23K 0.07% 344
2021
Q2 		$196K Sell
30,896
-7,125
-19% -$55.5K 0.08% 357
2021
Q1 		$294K Buy
38,021
+678
+2% +$5.37K 0.12% 244
2020
Q4 		$245K Sell
37,343
-1,378
-4% -$9.84K 0.1% 317
2020
Q3 		$257K Sell
38,721
-5,285
-12% -$39.2K 0.13% 255
2020
Q2 		$367K Sell
44,006
-6,220
-12% -$57.8K 0.17% 242
2020
Q1 		$385K Sell
50,226
-7,311
-13% -$51K 0.16% 201
2019
Q4 		$478K Buy
57,537
+33,236
+137% +$224K 0.08% 208
2019
Q3 		$179K Sell
24,301
-1,353
-5% -$13.3K 0.04% 266
2019
Q2 		$288K Buy
25,654
+7,569
+42% +$79.4K 0.06% 233
2019
Q1 		$194K Sell
18,085
-2,330
-11% -$34.4K 0.41% 91
2018
Q4 		$308K Buy
20,415
+1,565
+8% +$23.2K 0.05% 103
2018
Q3 		$349K Sell
18,850
-13,484
-42% -$307K 0.04% 178
2018
Q2 		$739K Sell
32,334
-2,542
-7% -$64.9K 0.65% 77
2018
Q1 		$992K Buy
34,876
+18,817
+117% +$537K 0.86% 43
2017
Q4 		$339K Sell
16,059
-8,018
-33% -$166K 0.43% 103
2017
Q3 		$437K Buy
24,077
+2,202
+10% +$34.4K 0.06% 101
2017
Q2 		$339K Buy
+21,875
New +$330K 0.05% 92

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtus ETF Advisers's CTMX Position: Q2 2022 in Review

Virtus ETF Advisers sold out of CytomX Therapeutics (CTMX) in Q2 2022, closing a stake of 25,634 shares — an estimated $68K sold.

Virtus ETF Advisers first reported a position in CTMX in Q2 2017 and held it in 20 quarters. The position peaked at $992K in Q1 2018. 98 funds tracked by Wall St. Rank hold CTMX as of Q2 2022.

  • Virtus ETF Advisers reported no remaining CytomX Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Virtus ETF Advisers sold 25,634 CytomX Therapeutics shares in Q2 2022, an estimated $68K.
  • Virtus ETF Advisers first reported a position in CytomX Therapeutics in Q2 2017 and held it in 20 quarters.
  • Virtus ETF Advisers's CytomX Therapeutics position peaked at $992K in Q1 2018.
  • 98 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2022.

Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.